Compare TFIN & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TFIN | ANIP |
|---|---|---|
| Founded | 1981 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | N/A | N/A |
| Metric | TFIN | ANIP |
|---|---|---|
| Price | $61.62 | $77.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $63.00 | ★ $107.33 |
| AVG Volume (30 Days) | 259.9K | ★ 419.1K |
| Earning Date | 01-26-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.22 | N/A |
| EPS | 0.93 | ★ 1.67 |
| Revenue | $435,852,000.00 | ★ $826,880,000.00 |
| Revenue This Year | $7.27 | $44.19 |
| Revenue Next Year | $11.31 | $11.25 |
| P/E Ratio | $66.41 | ★ $46.19 |
| Revenue Growth | 9.98 | ★ 48.87 |
| 52 Week Low | $42.90 | $54.10 |
| 52 Week High | $77.84 | $99.50 |
| Indicator | TFIN | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 43.55 | 38.53 |
| Support Level | $59.45 | $75.30 |
| Resistance Level | $70.66 | $83.80 |
| Average True Range (ATR) | 3.97 | 2.51 |
| MACD | -0.46 | -0.54 |
| Stochastic Oscillator | 19.79 | 20.59 |
Triumph Financial Inc is a financial holding company. The company has four reportable segments namely Banking, Factoring, Payments, and Intelligence. The Banking segment includes the operations of TBK Bank. The Factoring segment includes the operations of Triumph Financial Services with revenue derived from factoring services, The Payments segment includes the operations of TBK Bank's TriumphPay division which provides a presentment, audit and payment solution to Shipper, Broker, and Factor clients in the trucking industry and The Intelligence segment includes to turn the over-the-road trucking data collected through the services into actionable insights for their customers.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.